The United States Patent and Trademark Office (USPTO) granted US Patent No. 11,813,242 to Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing treatments for neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system disorders, for Anavex2-73 (blarcamesine), its leading drug candidate for treating insomnia, anxiety, or agitation.
The patent expands Anavex’s existing patent coverage of Anavex2-73, following US Patent No. 11,337,953, which the company received in May 2022.
This newest patent is expected to remain in force at least until July 2037, not including any patent term extension. Together with Anavex US Patent No. 11,337,953, which is expected to remain in force at least until 2038, not including any patent term extension, the two patents provide extensive coverage of Anavex2-73 for use in treating either insomnia or anxiety, used alone or in combination with Anavex19-144 or Anavex1-41.
The two patents broadly cover a range of dosage forms in treating known co-morbidities in Alzheimer’s disease including but not limited to oral, injectable, topical, inhalable, subcutaneous, intranasal, and sublingual dosage forms.
“This granted USPTO patent is not only another important milestone in protecting the commercial potential of Anavex2-73 (blarcamesine) and Anavex’s other lead compounds with the practical value of delivering holistic care for patients with Alzheimer’s dementia or Parkinson’s diseases, who often concurrently suffer from insomnia and/or anxiety, but along with other recent allowances, demonstrates our strong overall commitment to protecting the innovation and commercial opportunity of our entire product portfolio,” says Christopher U. Missling, PhD, president and CEO of Anavex, in a release.
Photo 127327341 © Jarretera | Dreamstime.com
